Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review

<div>Patient’s disease course timeline. Black arrow: Surgical resection of intramedullary metastasis at C6-7; Red arrow: stereotactic radiosurgery to 6, 9, and 11 brain lesions; SCLC: small-cell lung cancer; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; EP: etoposide/platinum; T: topotecan; PCI: prophylactic cranial irradiation; E: etoposide; Ev: everolimus; Tem: temozolamide; D: docetaxel; Su: sunitinib; LAD: lymphadenopathy; XRT: external beam radiation therapy.</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review 

Figure 2 | Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review 